Supernus to Present at Two Investor Conferences
ROCKVILLE, Md., May 20, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
the Company's management will present an overview of the Company at the
following investor conferences in May and June 2013:
Deutche Bank Conference:
Presentation Date: Thursday, May 30th
Time: 2:50 PM ET
Place: The Westin Boston Waterfront Hotel- Boston, MA
Presentation Date: Tuesday, June 4th
Time: 10:00 AM ET
Place: Grand Hyatt New York- New York, NY
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases.The Company has one approved product for
epilepsy, Oxtellar XR^TM (extended release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR^TM (extended release
topiramate).The Company is also developing several product candidates in
psychiatry to address large market opportunities in ADHD, including ADHD
patients with impulsive aggression. These product candidates include SPN-810
for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.